摘要
Lung cancer is the major cause of cancer-related mortality, accountingfor over one quarter of cancer deaths. Lung cancers are generally divided into two main categories： SCLC （small cell lung cancer） and NSCLC （non-small cell lung cancer）. NSCLC accounts for approximately 85% of all lung cancers. ALK （anaplastic largecell kinase） gene rearrangements are identified and targeted resulting in promising response rates for NSCLC in early studies. Ceritinib is a second-generation ALK inhibitor that has demonstrated activity in crizotinib （the first-generation ALK inhibitor）-resistant patients. In this paper, the synthesis, pharmacodynamics, pharmacokinetics, therapeutic trials, adverse events and drug-drug interactions are briefly overviewed in order to make more scholars, medical workers and patients have a more clear and comprehensive recognition on this drug.
